Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its clinical development pipeline consists of product candidates targeting hepatitis B virus (HBV), hepatitis delta virus (HDV) and human immunodeficiency virus (HIV). The Company also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). Its pipeline includes VIR-2218, VIR-3434, VIR-1388, VIR-7229, VIR-2482, VIR-2981, VIR-8190, and VIR-1949. VIR-2218 is an investigational HBV-targeting siRNA. VIR-1388 is an investigational HIV T cell vaccine based on human cytomegalovirus (HCMV).
VIR - Vir Biotechnology Inc
Report
There was a problem reporting this post.
Block Member?
Please confirm you want to block this member.
You will no longer be able to:
See blocked member's posts
Mention this member in posts
Please allow a few minutes for this process to complete.